Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT04605263

Deep Brain Stimulation (DBS) of the Pedunculopontine Nucleus (PPN)

This is a mechanistic study to determine the differential effects of the dopaminergic and cholinergic systems on attention, gait, and balance. The primary goal of the study is to evaluate the relative effects of pedunculopontine nucleus (PPN) and subthalamic nucleus (STN) Deep Brain Stimulation (DBS) on these features in persons with Parkinson's Disease (PD) who are eligible for DBS for improvement of their motor symptoms and exhibit gait instability with falls. Patients will be enrolled and implanted with bilateral electrodes in one of the approved DBS locations (subthalamic nucleus: STN), but additionally electrodes will be inserted into the experimental target, namely the PPN bilaterally.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

St. Joseph's Hospital & Medical Center / Barrow Neurological Institute

Phoenix, Arizona, 85013, United States

About this study

This is a prospective, single-center randomized controlled trial designed to estimate the potential clinical benefit, and associated risks, of deep brain stimulation of the of the PPN and STN in patients with PD that are candidates for DBS for improvement of their motor symptoms and exhibit gait instability with falls. Patients will be enrolled and implanted with additional bilateral electrodes in the PPN. Each subject will be randomized 1:1 to one of the following sequences: Bilateral STN+PPN stimulation or Bilateral STN stimulation alone. The addition of a bilateral STN stimulation only group allows for the research of potential micro-lesioning effects of the PPN which might affect features of interest even in the absence of PPN stimulation.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Inclusion Criteria
  • Informed consent signed by the subject.
  • Diagnosed with Parkinson's disease per UK Parkinson's Disease Society Brain Bank (Queens Square) criteria for at least 4 years
  • Demonstrates levodopa responsiveness of at least 30%
  • Experiences tremor or motor complications including wearing off and/or dyskinesia
  • DBS candidate per FDA guidelines as outlined in criteria 2-4
  • Candidate for STN targeting per the consensus committee
  • Subject exhibits gait instability, or a history of at least one fall within the last year, or a history of falls on tests of Static or Dynamic Stability.
  • PD Stage 2-3 with predominant axial symptoms or FOG refractory to Levodopa > 600 mg and UPDRS Part III Subscore of >6.
  • Subject is ambulatory and able to walk for limited periods of time without using an assistive device.
  • 18-75 years of age
  • Primary English speaking
  • Physically and cognitively capable of completing evaluations and consent
  • Medically cleared for surgery and anesthesia
  • Female subjects with child-bearing potential have a negative serum pregnancy test prior to DBS surgery

Exclusion criteria

Exclusion criteria

  • Dementia per DSM-V criteria
  • Condition precluding MRI
  • History of supraspinal CNS disease other than PD
  • History of schizophrenia, delusions, or currently uncontrolled visual hallucinations
  • Subjects who require rTMS, ECT, diathermy, or repeat MRI procedures to treat a medical condition.
  • Subjects with a history of seizure disorder
  • Subjects who have made a suicide attempt within the prior year,
  • Subjects with any medical contraindications to undergoing DBS surgery (eg, infection, coagulopathy, or significant cardiac or other medical risk factors for surgery)
  • Subjects with an implanted stimulator such as a cardiac pacemaker, defibrillator, neurostimulator and cochlear implant
  • Subjects who are pregnant or nursing.
  • Patient that is unwilling or unable to comply with the requirements of this protocol, including the presence of any condition (physical, mental, or social) that is likely to affect the subject's ability to comply with the protocol.
  • Any other reasons that, in the opinion of the investigator, the candidate is determined to be unsuitable for entry into the study.

Treatment and study plan

STN-PPN DBS Surgery

Device

Subject will undergo standard bilateral STN DBS surgery and have 2 additional leads placed in the same burr with bilateral PPN targets

Deep Brain Stimulation Surgery (DBS)

Procedure

DBS lead implantation of bilateral STN

Primary outcomes

  1. STN-PPN Stimulation Effect on Fall Risk

    Time frame: 27 months

    The purpose of this study is to measure the effect and the mechanism of deep brain stimulation (DBS) of the pedunculopontine nucleus (PPN) on fall risk as established by quantitative gait and balance analysis.

Secondary outcomes

  1. STN-PPN on Linear and Nonlinear Measures of Gait

    Time frame: 27 months

    Linear and nonlinear measured of gait will be measured during straight walking, turning, and arising and returning to a chair.

  2. STN-PPN on Linear and Nonlinear Measures of Balance

    Time frame: 27 months

    Linear and nonlinear measures of balance will be collected during eyes open, eyes closed, and perturbed (dyanic balance) conditions.

  3. STN-PPN on Attention

    Time frame: 27 months

    The effect of PPN stimulation, in comparison to that of STN alone, on attention, with be measured using the Conners Continuous Auditory Test of Attention and Continuous Performance Test 3.

  4. STN-PPN on Subjective Measures of Alertness

    Time frame: 27 months

    The effects of PPN stimulation on subjective function will be measured using the Toronto Alertness Scale, graded 0-50, with higher scores being better.

  5. STN-PPN on Subjective Measures of Sleep

    Time frame: 27 months

    The effects of PPN stimulation on subjective function will be measured using the Epworth Sleep Scale, graded 0-24, with lower scores being better.

  6. STN-PPN on Subjective Measures of Non-Motor Symptoms

    Time frame: 27 months

    The effects of PPN stimulation on subjective function will be measured using the Non-Motor Symptom Assessment, graded 0-360, with lower scores being better.

  7. STN-PPN on Subjective Measures of Balance in Daily Life

    Time frame: 27 months

    The effects of PPN stimulation on subjective function will be measured using the Activity-specific Balance Confidence Scale, graded on a scale of 0-100, with higher scores being better.

Sponsors and collaborators

Lead sponsor

St. Joseph's Hospital and Medical Center, Phoenix

Other

Collaborators

  • Arizona State University

Registry information

Official study title

Effects of Deep Brain Stimulation (DBS) of the Pedunculopontine Nucleus (PPN) on Gait, Postural Stability, Freezing of Gait (FOG), and Falls

Acronym: PPNGB01

Important dates

Study start
2021
Primary completion
2026
Study completion
2027
First posted
Oct 27, 2020
Registry last updated
Nov 29, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.